LANTUS SOLOSTAR
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LANTUS SOLOSTAR (LANTUS SOLOSTAR).
Insulin glargine is a recombinant human insulin analog with prolonged duration of action. It binds to insulin receptors, activating downstream signaling pathways including PI3K/Akt, leading to increased glucose uptake in peripheral tissues, inhibition of hepatic gluconeogenesis, and promotion of glycogenesis and lipogenesis. The long-acting profile is due to precipitation at subcutaneous injection site with slow absorption.
| Metabolism | Insulin glargine is partially degraded at the injection site into two active metabolites: M1 and M2. Systemic metabolism is minimal; it undergoes cleavage by peptidases to form inactive metabolites. |
| Excretion | Renal (minimal, intact drug not excreted), metabolized to inactive metabolites excreted renally and fecally; unchanged insulin glargine does not undergo significant renal excretion, degradation products excreted renally (~30%) and fecally (~70%). |
| Half-life | Terminal elimination half-life is 12.5 hours (range 10-18 hours) after subcutaneous administration due to prolonged absorption from the injection site, reflecting the duration of action. |
| Protein binding | Unbound, but nonspecific protein binding (albumin) is minimal; insulin glargine does not bind to insulin-like growth factor binding proteins, binding to serum albumin < 1%. |
| Volume of Distribution | 0.4 L/kg (range 0.3-0.6 L/kg) in type 1 diabetes, reflecting distribution into interstitial fluid. |
| Bioavailability | Subcutaneous: approximately 60-80% (relative to intravenous) due to degradation at injection site; absolute bioavailability ~60%. |
| Onset of Action | Subcutaneous: approximately 1 hour (range 0.5-2 hours) with a flat, prolonged profile. |
| Duration of Action | Subcutaneous: up to 24 hours (range 22-26 hours) due to slow dissolution of microprecipitates; allows once-daily dosing, but duration may vary with dose and injection site. |
Injection, subcutaneous: initial: 0.2 units/kg once daily, typical maintenance: 0.5-1 unit/kg once daily, max: 80 units/day.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment recommended; use caution. GFR <30 mL/min: monitor glucose closely; decreased insulin requirements may occur. |
| Liver impairment | No specific guidelines; Child-Pugh class A, B, C: monitor glucose closely; impaired hepatic function may reduce gluconeogenesis, increasing hypoglycemia risk. |
| Pediatric use | Children ≥6 years: weight-based dosing: initial: 0.2-0.5 units/kg once daily; titrate based on glycemic control. <6 years: safety not established. |
| Geriatric use | Elderly: initiate with 1-2 units once daily, titrate slowly due to increased hypoglycemia risk; monitor renal function and cognitive status. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LANTUS SOLOSTAR (LANTUS SOLOSTAR).
| Breastfeeding | Safety during breastfeeding is established. Endogenous insulin is present in breast milk, but recombinant insulin is not absorbed orally by the infant. There is no available M/P ratio for insulin glargine. The drug is considered compatible with breastfeeding; monitor infant for hypoglycemia, though risk is minimal. |
| Teratogenic Risk | Insulin glargine does not cross the placenta in significant amounts. No fetal harm is expected based on animal studies and clinical experience. However, severe maternal hypoglycemia or hyperglycemia can independently cause fetal harm. Insulin glargine is considered low risk during all trimesters; use is indicated if required for glycemic control. |
■ FDA Black Box Warning
Not indicated for treatment of diabetic ketoacidosis. Dose adjustment required for concomitant use of thiazolidinediones or insulin secretagogues due to increased risk of hypoglycemia.
| Common Effects | Hypoglycemia low blood glucose level Peripheral edema Lipodystrophy skin thickening or pits at the injection site Allergic reaction Injection site reactions pain swelling redness Itching Rash Weight gain |
| Serious Effects |
["Hypersensitivity to insulin glargine or any excipients","During episodes of hypoglycemia"]
| Precautions | ["Hypoglycemia: Most common adverse reaction; patient education on recognition and management required.","Never share pens between patients; risk of bloodborne pathogen transmission.","Hypokalemia: May occur, monitor serum potassium in patients at risk.","Accidental mix-up with other insulins: Carefully check label before administration.","Changes in insulin regimen may precipitate diabetic ketoacidosis or hyperglycemia.","Use with caution in patients with hepatic or renal impairment: increased risk of hypoglycemia.","Medication errors: Do not administer intravenously or intramuscularly; intended for subcutaneous use only."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood glucose and HbA1c regularly throughout pregnancy. Fetal surveillance via ultrasound for growth anomalies and well-being is recommended due to maternal diabetes. Close monitoring for maternal hypoglycemia is required, especially as pregnancy progresses. |
| Fertility Effects | No direct adverse effects on fertility in animal studies. Uncontrolled diabetes can impair fertility via hormonal disturbances and ovulatory dysfunction. Proper glycemic control with insulin glargine may improve fertility outcomes in diabetic patients. |